Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy
Status: Enrolling
Updated:  2/1/2018
Geisinger Health System
mi
from
Danville, PA
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy
Status: Enrolling
Updated: 2/1/2018
Geisinger Health System
mi
from
Danville, PA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Stanford University
mi
from
Stanford, CA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
University of Colorado
mi
from
Aurora, CO
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
University of Chicago
mi
from
Chicago, IL
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Johns Hopkins University
mi
from
Baltimore, MD
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Children's Hospital Boston
mi
from
Boston, MA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Vanderbilt University
mi
from
Nashville, TN
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Toronto General Hospital
mi
from
Toronto,
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Toronto General Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Cinncinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Cinncinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Hospital
mi
from
Oakland, CA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Memorial Hospital
mi
from
Chicago, IL
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Hospital
mi
from
Boston, MA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated:  2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Thalassemia Clinical Research Network - Cardiac L1/DFO Trial
Status: Enrolling
Updated: 2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2
Status: Enrolling
Updated:  2/2/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2
Status: Enrolling
Updated: 2/2/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3
Status: Enrolling
Updated:  2/2/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3
Status: Enrolling
Updated: 2/2/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cangrelor to Clopidogrel or Prasugrel Transition Study
A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.
Status: Enrolling
Updated:  2/4/2018
Fletcher Allen Health Care
mi
from
Burlington, VT
Cangrelor to Clopidogrel or Prasugrel Transition Study
A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.
Status: Enrolling
Updated: 2/4/2018
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
Morehouse School of Medicine
mi
from
Atlanta, GA
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
Morehouse School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
Minnesota Heart Failure Network
mi
from
Minneapolis, MN
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
Minnesota Heart Failure Network
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
Baylor College of Medicine
mi
from
Houston, TX
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
University of Utah Health Sciences Center
mi
from
Murray, UT
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
University of Utah Health Sciences Center
mi
from
Murray, UT
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
University of Vermont/Fletcher Allen Health Care
mi
from
Burlington, VT
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
University of Vermont/Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated:  2/5/2018
Montreal Heart Institute
mi
from
Montréal,
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Status: Enrolling
Updated: 2/5/2018
Montreal Heart Institute
mi
from
Montréal,
Click here to add this to my saved trials
iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.
Imaging iNOS Activity Using [18F] (+/-) NOS With Positron Emission Tomography (PET) in Cellular Inflammation.
Status: Enrolling
Updated:  2/5/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.
Imaging iNOS Activity Using [18F] (+/-) NOS With Positron Emission Tomography (PET) in Cellular Inflammation.
Status: Enrolling
Updated: 2/5/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Fatty Acid Radiotracer Comparison Study in Heart Failure Patients
Measurements of Myocardial Fatty Acid Metabolism With PET and [F-18]FluorbetaOx in Humans With Heart Failure With and Without Diabetes: Comparison With [C-11]Palmitate
Status: Enrolling
Updated:  2/5/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Fatty Acid Radiotracer Comparison Study in Heart Failure Patients
Measurements of Myocardial Fatty Acid Metabolism With PET and [F-18]FluorbetaOx in Humans With Heart Failure With and Without Diabetes: Comparison With [C-11]Palmitate
Status: Enrolling
Updated: 2/5/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Status: Enrolling
Updated:  2/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Status: Enrolling
Updated: 2/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease
Status: Enrolling
Updated:  2/5/2018
National Jewish Health
mi
from
Denver, CO
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease
Status: Enrolling
Updated: 2/5/2018
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
Fletcher Allen Health Care
mi
from
Burlington, VT
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
VA San Diego Healthcare System
mi
from
San Diego, CA
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
VA San Diego Healthcare System
mi
from
San Diego, CA
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
University of California, San Diego
mi
from
San Diego, CA
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
University of Utah Health Care, Utah
mi
from
Salt Lake City, UT
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
University of Utah Health Care, Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated:  2/6/2018
University of Wisconsin-Madison
mi
from
Madison, WI
AC6 Gene Transfer for CHF
Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure
Status: Enrolling
Updated: 2/6/2018
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Reversal of Obese/Diabetic Cardiomyopathy After Gastric Bypass Surgery
Reversal of Obesity- and Diabetes-related Cardiomyopathy in Patients Who Have Undergone Gastric Bypass Surgery.
Status: Enrolling
Updated:  2/6/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Reversal of Obese/Diabetic Cardiomyopathy After Gastric Bypass Surgery
Reversal of Obesity- and Diabetes-related Cardiomyopathy in Patients Who Have Undergone Gastric Bypass Surgery.
Status: Enrolling
Updated: 2/6/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
Prospective Analysis of Low-Dose Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
Status: Enrolling
Updated:  2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
Prospective Analysis of Low-Dose Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
Status: Enrolling
Updated: 2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Reversal of Obesity Cardiomyopathy
Reversal of Obesity Cardiomyopathy After Gastric Bypass
Status: Enrolling
Updated:  2/6/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Reversal of Obesity Cardiomyopathy
Reversal of Obesity Cardiomyopathy After Gastric Bypass
Status: Enrolling
Updated: 2/6/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Early Warning System for Clinical Deterioration on General Hospital Wards
Early Warning System for Clinical Deterioration on General Hospital Wards.
Status: Enrolling
Updated:  2/7/2018
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Early Warning System for Clinical Deterioration on General Hospital Wards
Early Warning System for Clinical Deterioration on General Hospital Wards.
Status: Enrolling
Updated: 2/7/2018
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated:  2/7/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Status: Enrolling
Updated: 2/7/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials